| Name | Reverse transcriptase-IN-1 |
| Description | Reverse transcriptase-IN-1 is a diarylbenzopyrimidine (DABP) analogue and a potent inhibitor of HIV-1 nonnucleoside reverse transcriptase with an IC50of 13.7 nM. |
| In vitro | Reverse transcriptase-IN-1 has antiviral activity with EC50 values of 3.4 nM, 4.3 nM and 3.6 nM for HIV-1 IIIB, E138K and K103N mutants, respectively[1]. |
| In vivo | The PK study and safety assessment of Reverse transcriptase-IN-1 shows that it is absorbed with mean residence times (MRTs) of 11.8 hours (5 mg/kg, p.o.) and 11.4 hours (1 mg/kg, i.v.) at these two doses. The Cmax of Reverse transcriptase-IN-1 is 39.9 ng/mL at a dose of 5 mg/kg. The oral bioavailability of Reverse transcriptase-IN-1 is significantly improved to 16.5% at a dose of 5 mg/kg in rats. The intrinsic rat microsome clearance of Reverse transcriptase-IN-1 is 33.2 μL/min/mg proteins[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.23 mM), Sonication is recommended.
DMSO : 12 mg/mL (26.82 mM), Sonication and heating to 60℃ are recommended.
|
| Keywords | Reverse transcriptase-IN-1 | Reverse transcriptaseIN1 | Reverse transcriptase IN 1 | Inhibitor | inhibit | Human immunodeficiency virus | HIVProtease | HIV-1 reverse transcriptase | HIV-1 | HIV Protease | HIV |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Emtricitabine | Indole-2-carboxylic acid | Dimethyl fumarate | Lamivudine | Valproic Acid | Chloroquine | (-)-Epigallocatechin Gallate | Decanedioic acid | Dextran sulfate sodium salt (MW 5000) | Bromhexine hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Bioactive Compound Library Plus | Anti-Viral Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Infection Compound Library |
United States
